PepGen (PEPG) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed PepGen (PEPG) over the past year, losing 4.6% versus a loss of 47.9%. Yarrow Bioscience is the larger company by market cap ($183.4 million vs $181.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | YARW |
|---|---|---|
| Share price | $2.62 | $19.71 |
| Market cap | $181.22M | $183.39M |
| 1-day change | +10.08% | -0.81% |
| YTD return | -59.75% | -32.03% |
| 1-year return | -47.91% | -4.55% |
| 5-year return | — | -98.20% |
| EPS (TTM) | $-1.01 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.80 | $46.95 |
| 52-week low | $1.31 | $16.05 |
| Distance from 52-week high | -66.41% | -58.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +288.93% | +189.19% |
| Average volume | 923.99K | 85.28K |
| Shares outstanding | 69.17M | 9.30M |
| Employees | 57 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed PEPG by 43.4 percentage points over the past year.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Healthcare · Biotechnology · 7 employees
PEPG vs YARW FAQ
Which is bigger, PepGen or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $183.39M compared with $181.22M for PepGen (PEPG).
Which stock has performed better over the past year, PEPG or YARW?
YARW returned -4.55% over the past 12 months, compared with -47.91% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.